Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Get your questions posted!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Comment by narmacon Jun 20, 2022 5:22pm
142 Views
Post# 34769785

RE:RE:RE:RE:RE:Get your questions posted!

RE:RE:RE:RE:RE:Get your questions posted!Can you say,,,,,,toooo dahhhhh moooon,,,,,nasdaq,,,,,and also several entities in discussion around our 001 platform!!!,,,,,the landscape is changing,,,,,,and it can change with the stroke of a pen now,,,,,and the new developments are clearly an advantage to us more than Cresence imo,,,,,,,and all the while we wait on clinical trial/s with our xB3 partners. I like it!!,,,,minimal cost for a huge gain in the level of drug development,,,DrDR you hit one out of the park this time!!!,,,,,,,,we are under the radar,,,but for how long is the question,,,,,,Mei Mei never had a chance to chat,,but her expertise is xB3,,,,,,,get 'em while you can!!!....cuz more exciting news cant be far away,,,,,,,,woooooohooooooo!!!,,,
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities